No Data
Xintiandi (301277.SZ): Active Pharmaceutical Ingredient of etomidate approved for market launch.
On January 7, Gelonghui reported that on January 6, 2025, New World Pharmaceutical Co., Ltd. received the "Approval Notice for the Listing Application of Chemical Raw Materials for Active Pharmaceutical Ingredients" issued by the National Medical Products Administration for Etomidate. Etomidate is an imidazole derivative and a non-barbiturate intravenous anesthetic, used as a rapid-acting hypnotic intravenous general anesthetic for induction of intravenous general anesthesia or as an adjunct for anesthesia, as well as for short surgical anesthesia.
New World (301277.SZ): The construction project for an annual production of 120 tons of Active Pharmaceutical Ingredient is expected to reach its intended usable state by November 2025.
Gelonghui, December 30th丨New World (301277.SZ) stated on the investor interaction platform that the "120 Tons Active Pharmaceutical Ingredient Production Project" is progressing steadily, expected to be operational by November 2025. Due to market conditions and other factors, the production status depends on various changes in internal and external environments, and there is a certain level of uncertainty.
Xintiandi (301277.SZ) received the second phase of grant funding for a certain project amounting to 7.3 million yuan.
Xintiandi (301277.SZ) announced that the company recently received the second batch of funding for a certain project, amounting to ...
Chao News | The Breitling boutique in Taikoo Li, Shanghai opens; JNBY "Art Education" launches its first class in Shanghai; Tickets for the 2025 F1 Heineken NV Sponsored ADR Chinese Grand Prix are now on sale; GENTLE MONSTER's flagship store in Xintiandi,
The new Breitling store invites Consumers to experience the diversity presented by "land, sea, and air," as well as the adventurous spirit and vitality of breaking conventions.
Talent ppt gp (00760.HK): Zhou Hanlu has been appointed as a non-executive director.
Gelonghui, December 9: TALENT PPT GP (00760.HK) announced that Zhou Hanlu has been appointed as a non-executive Director of the company, effective from December 9, 2024.
Xintiandi (301277.SZ): The company's pharmaceutical production license has been modified, involving expanding the production scope.
On December 2, Gelonghui reported that Xintiandi (301277.SZ) announced that it recently obtained the renewed "Pharmaceutical Manufacturing License" from the Henan Provincial Drug Administration, approving the change application for the "Pharmaceutical Manufacturing License". This change mainly involves an expansion of the production scope: active pharmaceutical ingredients including benzenesulfonic acid amlodipine, fondaparinux sodium, benzenesulfonic acid lefamulin, and phosphoric acid lupeol, along with supporting production workshops and production lines, while other contents remain unchanged. The change in the company's "Pharmaceutical Manufacturing License" mainly involves changes in the production scope and the conditions of the production workshops and production lines, which is beneficial for enriching the company's product structure and will have a long-term impact on the company's market expansion.
No Data